These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 34019703)

  • 1. Evaluation of the relationship between KIM-1 and suPAR levels and clinical severity in COVID-19 patients: A different perspective on suPAR.
    Kerget B; Kerget F; Aksakal A; Aşkın S; Uçar EY; Sağlam L
    J Med Virol; 2021 Sep; 93(9):5568-5573. PubMed ID: 34019703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of Serum Pentraxin-3 and suPAR Levels as Acute Phase Reactants in Patients with COVID-19].
    Akbayırlı U; Kaya S; Aksoy Gökmen A
    Mikrobiyol Bul; 2022 Oct; 56(4):631-644. PubMed ID: 36458710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19.
    Sarif J; Raychaudhuri D; D'Rozario R; Bandopadhyay P; Singh P; Mehta P; Hoque MA; Sinha BP; Kushwaha M; Sahni S; Devi P; Chattopadhyay P; Paul SR; Ray Y; Chaudhuri K; Banerjee S; Majumdar D; Saha B; Sarkar BS; Bhattacharya P; Chatterjee S; Paul S; Ghosh P; Pandey R; Sengupta S; Ganguly D
    Front Immunol; 2021; 12():738093. PubMed ID: 34777349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study.
    Oulhaj A; Alsuwaidi AR; Suliman A; Gasmelseed H; Khan S; Alawi S; Hukan Y; George J; Alshamsi F; Sheikh F; Babiker ZOE; Prattes J; Sourij H
    Int J Infect Dis; 2021 Jun; 107():188-194. PubMed ID: 33862208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble urokinase plasminogen activator receptor levels are predictive of COVID-19 severity in Afro-Caribbean patients.
    Padelli M; Gueye P; Guilloux D; Banydeen R; Campana V; Cabie A; Neviere R
    Biomark Med; 2022 Feb; 16(3):169-177. PubMed ID: 35081737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the Circulating Supar Levels with Inflammation, Fibrinolysis, and Outcome in Severe Burn Patients.
    Lin JC; Chen XD; Xu ZR; Zheng LW; Chen ZH
    Shock; 2021 Dec; 56(6):948-955. PubMed ID: 34779798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.
    Azam TU; Shadid HR; Blakely P; O'Hayer P; Berlin H; Pan M; Zhao P; Zhao L; Pennathur S; Pop-Busui R; Altintas I; Tingleff J; Stauning MA; Andersen O; Adami ME; Solomonidi N; Tsilika M; Tober-Lau P; Arnaoutoglou E; Keitel V; Tacke F; Chalkias A; Loosen SH; Giamarellos-Bourboulis EJ; Eugen-Olsen J; Reiser J; Hayek SS;
    J Am Soc Nephrol; 2020 Nov; 31(11):2725-2735. PubMed ID: 32963090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients.
    Lippi G; Henry BM; Favaloro EJ
    Clin Chem Lab Med; 2021 Oct; 59(11):e413-e415. PubMed ID: 34116589
    [No Abstract]   [Full Text] [Related]  

  • 9. Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department.
    Stauning MA; Altintas I; Kallemose T; Eugen-Olsen J; Lindstrøm MB; Rasmussen LJH; Gamst-Jensen H; Nehlin JO; Andersen O; Tingleff J
    J Emerg Med; 2021 Sep; 61(3):298-313. PubMed ID: 34092446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction value of soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients - a systematic review and meta-analysis.
    Matuszewski M; Ładny J; Rafique Z; Peacock F; Pruc M; Gasecka A; Szwed P; Jankowski L; Chmielewski J; Panasiuk L; Szarpak L
    Ann Agric Environ Med; 2023 Mar; 30(1):142-147. PubMed ID: 36999867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.
    Rovina N; Akinosoglou K; Eugen-Olsen J; Hayek S; Reiser J; Giamarellos-Bourboulis EJ
    Crit Care; 2020 Apr; 24(1):187. PubMed ID: 32354367
    [No Abstract]   [Full Text] [Related]  

  • 12. Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker in COVID-19 patients: a systematic review.
    Lobato-Martínez E; Sanchez-Martinez R; de-Miguel Balsa E; Ramos-Rincon JM
    Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):852-860. PubMed ID: 38305628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID-19: The International Study of Inflammation in COVID-19.
    Vasbinder A; Padalia K; Pizzo I; Machado K; Catalan T; Presswalla F; Anderson E; Ismail A; Hutten C; Huang Y; Blakely P; Azam TU; Berlin H; Feroze R; Launius C; Meloche C; Michaud E; O'Hayer P; Pan M; Shadid HR; Rasmussen LJH; Roberts DA; Zhao L; Banerjee M; Murthy V; Loosen SH; Chalkias A; Tacke F; Reiser J; Giamarellos-Bourboulis EJ; Eugen-Olsen J; Pop-Busui R; Hayek SS;
    J Med Virol; 2024 Jan; 96(1):e29389. PubMed ID: 38235904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis.
    Huang F; Li Y; Xu R; Cheng A; Lv Y; Liu Q
    Mediators Inflamm; 2020; 2020():7850179. PubMed ID: 32322165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble urokinase plasminogen activator receptor associates with higher risk, advanced disease severity as well as inflammation, and might serve as a prognostic biomarker of severe acute pancreatitis.
    Zhang Q; Li L; Chen H; Zhang G; Zhu S; Kong R; Chen H; Wang G; Sun B
    J Clin Lab Anal; 2020 Mar; 34(3):e23097. PubMed ID: 31774228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19.
    Luo S; Vasbinder A; Du-Fay-de-Lavallaz JM; Gomez JMD; Suboc T; Anderson E; Tekumulla A; Shadid H; Berlin H; Pan M; Azam TU; Khaleel I; Padalia K; Meloche C; O'Hayer P; Catalan T; Blakely P; Launius C; Amadi KM; Pop-Busui R; Loosen SH; Chalkias A; Tacke F; Giamarellos-Bourboulis EJ; Altintas I; Eugen-Olsen J; Williams KA; Volgman AS; Reiser J; Hayek SS;
    J Am Heart Assoc; 2022 Sep; 11(18):e025198. PubMed ID: 35924778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Perspective of Vitamin D on suPAR-Related AKI in COVID-19.
    Liao TH; Wu HC; Liao MT; Hu WC; Tsai KW; Lin CC; Lu KC
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma level of soluble urokinase plasminogen activator receptor (suPAR) predicts long-term mortality after first acute alcohol-induced pancreatitis.
    Aronen A; Aittoniemi J; Huttunen R; Nikkola A; Nikkola J; Limnell O; Nordback I; Sand J; Laukkarinen J
    Eur J Intern Med; 2019 Jun; 64():72-75. PubMed ID: 31060962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open label trial of anakinra to prevent respiratory failure in COVID-19.
    Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ
    Elife; 2021 Mar; 10():. PubMed ID: 33682678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study.
    Segala FV; Rando E; Salvati F; Negri M; Catania F; Sanmartin F; Murri R; Giamarellos-Bourboulis EJ; Fantoni M
    PLoS One; 2023; 18(4):e0273202. PubMed ID: 37014833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.